Muscles, fats and simple blood test can predict menopausal women's health
It is also practical and cheaper than current methods of measuring muscle, such as the current gold standard magnetic resonance imaging scans or strength tests, which are also more time-consuming.
This new insight from a longitudinal cohort study of midlife women in Singapore shone light on how muscle strength, visceral fat and their association with physical decline after menopause can potentially lead to downstream health impacts among women here.
Researchers from the National University Hospital (NUH) and National University of Singapore (NUS) found that women with a lower creatinine-to-cystatin C ratio (CCR) – a marker derived from blood tests – had less muscle and walked more slowly as they age.
Creatinine is a by-product of normal muscle function and energy use, and a higher level indicates higher skeletal muscle mass or poor kidney function.
Cystatin C is a protein produced by the body's cells that is filtered out by the kidneys. A normal cystatin C level rules out poor kidney function.
A low CCR of under 8.16 was associated with a lower muscle volume of 0.35 litres in the thigh, and a slower gait of 0.049m a second.
This suggested that CCR could be a useful early warning sign for age-related muscle loss, which may lead to falls, frailty and reduced quality of life.
The findings were published in Menopause, a monthly peer-reviewed journal, in March.
The scientists involved in the study are from the Integrated Women's Health Programme (IWHP) at NUH and the NUS Yong Loo Lin School of Medicine.
The IWHP was initiated to identify and address the healthcare needs of midlife Singaporean women. It recruited a cohort of 1,200 Chinese, Malay and Indian women aged 45 to 69 between 2014 and 2016 – about 70 per cent of whom were post-menopausal. Their health metrics were then tracked over time.
In the first study based on this cohort, published in international journal Maturitas in October 2023, the researchers shared a ranking of menopausal symptoms – with joint and muscular discomfort found to be the most reported symptom among women in Singapore.
Called arthralgia, it had moderate or severe impact on a third of the midlife women of the cohort.
A subsequent study, published in the Diabetes, Obesity and Metabolism journal in October 2024, found that women with both weak muscle strength and high levels of visceral fat – the deep belly fat around the internal organs – had the highest risk of developing prediabetes or type 2 diabetes.
Their risk was 2.63 times higher than that of women who had normal muscle strength and lower fat levels.
Having just one of these conditions also increased their risk, though to a lesser degree. The risk from having high visceral fat alone is 1.78 times higher. Among those with weak muscle strength, women with high visceral fat faced 2.84 times as much risk compared with those with low visceral fat.
Explaining the impetus for the study, IWHP lead Yong Eu Leong said: 'Muscle... burns up fat. What about those who have weak muscles? Does it affect the risk for diabetes in the future?'
The cohort's initial muscle and visceral fat measurements served as a baseline for researchers to track changes over the years.
Researchers then analysed how changes in fat and muscle measurements taken about six years later – by then, about 90 per cent of the women were post-menopausal – related to whether women had developed diabetes.
Professor Yong, who also heads the division of benign gynaecology in the Department of Obstetrics and Gynaecology at NUH, noted that a large proportion of women in Singapore are 'skinny fat', where their body mass index is within the normal range, but that they have high levels of visceral fat and low muscle mass.
'One way (to know what your risks are) is to measure your walk and the speed at which you walk. If you cannot walk fast and straight, then your health is not so good. We wanted to see if we can develop a test that can predict gait speed. We wanted to look at molecules that actually measure muscle functions,' he said.
'These findings validated our previous (IWHP) research that showed that women should not just focus on weight loss, but on building muscle strength through exercise for diabetes prevention,' Prof Yong said.
One participant of the IWHP, administrative assistant Sabarina Jumarudin, is living proof of the findings.
The 59-year-old grandmother used to weigh 93kg and suffered from sleep apnoea.
Since undergoing bariatric surgery at NUH in 2018, a procedure that modifies the digestive system to help people with obesity lose weight, she has lost more than 30kg.
Mindful of keeping her weight down, Madam Sabarina walks to the MRT station every day instead of taking the shuttle service, and takes the stairs instead of the escalator to catch the train.
'On my way home, I usually take a longer route to ensure I clock at least 10,000 steps a day, and practise stretching and breathing exercises to strengthen my core,' she said.
'I realised that small but consistent changes do make a big impact on my health, so I do what I can on a daily basis, and it gives me confidence to not only stay healthy physically and mentally but also stave off diabetes,' she added.
Source: The Straits Times © SPH Media Limited. Permission required for reproduction
Discover how to enjoy other premium articles here
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
AstraZeneca launches at-home FluMist nasal spray delivery
AstraZeneca is making flu protection more convenient with the launch of an at-home delivery option for FluMist, its nasal spray flu vaccine, the company announced Friday. On the market since 2003, FluMist was previously only available at pharmacies or doctors' offices. FDA approves nasal spray flu vaccine Beginning Friday, eligible customers can order it online and have it shipped directly to their door, allowing parents to vaccinate their children at home without shots or a trip to the pharmacy. The spray can be self-administered by adults up to age 49, while caregivers can give it to children ages 2–17, the company said. The FDA approved FluMist for self- and caregiver-administration in September 2024, after research showed adults over 18 could safely and effectively administer it to eligible individuals. AstraZeneca hopes the needle-free option and at-home convenience will boost vaccination rates this year. Last year's flu season saw the highest number of flu-related deaths for children for a non-pandemic year -- 267 -- since the 2009 H1N1 pandemic, according to the Centers for Disease Control and Prevention. Health experts stress that vaccination remains the best protection against the virus, though getting kids vaccinated can be a challenge. The CDC continues to recommend that everyone 6 months and older get a flu vaccine this fall. Most health insurance plans are expected to cover the cost, with a shipping fee for four FluMist doses estimated at under $10. The company added for those who qualify, the nasal spray offers safety and effectiveness comparable to traditional flu shots. Solve the daily Crossword


Forbes
17 minutes ago
- Forbes
The Future Of Healthcare Is At A Dinner Table, Not An Operating Room
Robin Shah, Co-founder and Chief Executive Officer of Thyme Care. Imagine a healthcare system that anticipates the needs people might not even consider. Where our right elbow pain isn't treated in isolation but as one aspect of a connected web that includes our sleep, stress levels and daily activities. Where we're proactively provided with information on all our health-related needs, alongside details on how they're connected, the costs we will incur and our access to community resources and insurance navigation support. Healthcare leaders today might struggle to envision a roadmap that can turn this healthcare fantasy into reality, especially given the turbulence and uncertainty currently affecting our healthcare ecosystem. However, I believe it's not just a clinical imperative to get on board with this future state of healthcare—it's a business survival strategy. The Inevitable Shift To Co-Created Care Today, healthcare happens to us rather than with us. It's a passive approach that reduces symptoms to mere statistics at appointments, after diagnosis and during emergencies. Despite new innovations and medical advancements, people are sicker and more stressed than ever before. I imagine the future of care will look less like an operating room and more like a dinner table. Guests will be handpicked clinical experts, along with experts with broader roles who consider the whole patient: navigators, behavioral health therapists, nutritionists, fitness coaches and health plan experts. These experts will intimately know their patients and be able to champion their needs. Patients will be informed collaborators in care, communicating their preferences, participating in planning discussions and taking ownership of preventative behaviors. This is what a co-created healthcare model looks like, but it'll only be possible when our collective ecosystem—hospitals and clinics, digital health innovators, policymakers and payers—commit to redesigning care models so they reward patient engagement, care coordination and shared decision making. No one leader, company or group can do it alone. The Technological, Economic And Human Levers Reshaping Care When it comes to co-created care, we're already seeing promising changes at the micro- and meso-levels that hint at what's to come. Today's remote monitoring systems, for example, track conditions like diabetes and heart disease in real time. Patient navigators help people understand and manage our complex health systems. Telehealth platforms improve access to care. These changes required leaders and innovators to drop traditional workflows and behaviors and create new ways to engage with healthcare. We need to keep pushing what's possible because incremental improvements won't deliver the dinner-table healthcare experience we need—not without a total redesign of the ecosystem. Here are some ways we can move to these macro-level changes: AI-Supported Care Everywhere I believe the most powerful lever propelling us toward a brighter healthcare future is artificial intelligence. It looks to transform healthcare faster than the smartphones that revolutionized how we communicate with each other. Consider this: The iPhone launched in 2007, and 10 to 15 years later, nearly everyone has a powerful minicomputer in their pocket. I see AI having a similar impact in healthcare but with an accelerated timeline. However, I don't predict that AI will replace the human element of healthcare altogether. Instead, I see it amplifying experts' roles. When radiologists validate mammogram readings, they'll be backed by technology that delivers the collective wisdom of thousands of similar scans to account for all possible scenarios. This combination of AI insights with human interpretation has the potential to create cohesive care strategies that neither technology nor humans could achieve separately. An Economic Model That Rewards Quality Care The U.S. system rewards individual, high-cost points of intervention while delivering poorer quality and outcomes. This is not sustainable from a cost perspective. To avoid reaching a breaking point, we must embrace the shift from transactional care to comprehensive support. For this to happen, system-wide adoption of a model that rewards outcomes, experience and effectiveness will be required. Although most healthcare organizations recognize the benefits of value-based care and are beginning to adopt and implement programs, broader adoption of value-based care by both governmental and private insurance is crucial for its success. Today, when someone receives a cancer diagnosis, they frantically coordinate between oncologists, surgeons, mental health professionals and insurance representatives. The patient shoulders the burden of orchestrating their own complex care. With a co-created care model, patients can feel supported from the moment of diagnosis by a team that anticipates their needs. Patients In The Driver's Seat In every walk of life, expectations are shifting—we want immediate access to the service we need, along with all the right information at our fingertips to give us the maximal experience. Why do we expect less in healthcare, especially when it comes to conditions like cancer? Since we're paying top dollar for care, why isn't every experience like walking into the Four Seasons? Patients facing a fear-inducing diagnosis don't want to wait weeks for answers. They're starting to demand immediate access to support and resources, and they're willing to find a new provider if they're unhappy with their current one. This is the rising tide we need. Patient self-advocacy and demand for change create market pressure that will force healthcare organizations to revisit certain aspects of the care model. I anticipate today's clunky portals will eventually become connected devices, readily serving patients information about their care as needed. Hospitals and clinics will also look at restructuring how they engage with patients during and between appointments, bringing them into decisions about treatment pathways, medication options and care facility preferences rather than "assigning" care plans. This way, patients are more active participants in their health management and feel equally responsible for their outcomes. Collective Action The onus for this future state of healthcare is on all of our shoulders. As healthcare leaders, policy experts and consumers of care, we must watch for moments of change that can accelerate the evolution already underway. Any step in the right direction is a win, and although progress may feel challenging at the moment, we need to continue moving forward. I am certain that, soon, we'll be embracing and celebrating a healthcare system that finally works with and for people. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Yahoo
30 minutes ago
- Yahoo
A real-life Pandora? Newfound 'disappearing' planet in our neighboring star system could have a habitable moon, just like the Avatar movies
When you buy through links on our articles, Future and its syndication partners may earn a commission. A potential gas giant recently discovered orbiting in the habitable zone of one of the closest stars to Earth could have a moon capable of sustaining life — just like the alien world "Pandora" from the "Avatar" movies, researchers have speculated. However, there is currently no evidence to suggest that such a moon exists or that it could support life. In fact, scientists are still unsure if its host planet is actually where they think it is. A study published Aug. 11 in The Astrophysical Journal Letters revealed the potential discovery of a Saturn-size gas giant, dubbed S1, orbiting Alpha Centauri A — one of three stars that make up the Alpha Centauri system, which lies roughly 4.25 light-years from our own solar system. The potential exoplanet, which likely orbits its home star at up to twice the distance between Earth and the sun, was initially spotted by the James Webb Space Telescope (JWST) in August 2024. However, the powerful telescope failed to spot the world again when it was expected to become visible in February and April this year, leading to it being dubbed a "disappearing planet." Researchers believe that S1's orbit may have moved it in front of Alpha Centauri A, making it much harder for JWST to spot the gas giant. By their calculations, it should become visible again in 2026 and 2027, meaning we will need to wait a few more years before we can be certain of its existence. But if it is eventually confirmed, "It would be the most significant JWST discovery to date," study co-author Stanimir Metchev, an exoplanet researcher at Western University in Ontario, told Live Science. Related: Proposed spacecraft could carry up to 2,400 people on a one-way trip to the nearest star system, Alpha Centauri To date, only two planets have been confirmed within our adjacent neighborhood, both of which orbit Proxima Centauri — the closest star to Earth, which circles the binary star pair of Alpha Centauri A and Alpha Centauri B. But as our closest stellar neighbors, the idea of traveling to Alpha Centauri and potentially establishing a human colony there has long piqued humanity's interest in both science and science fiction. The triple stars' most notable sci-fi inclusion is probably in the "Avatar" franchise, as the home system of Pandora — the fictional homeworld of the blue-skinned aliens, known as the Na'vi, who go to war with humans who invade the moon (which purportedly orbits a gas giant) after traveling to Alpha Centauri on interstellar starships in the 22nd century. Interestingly, S1 is likely around the same size as Polyphemus, the fictional gas giant orbited by Pandora. And both S1 and Polyphemus also supposedly reside within Alpha Centauri A's habitable zone, where there are suitable conditions for extraterrestrial life to emerge. Real-life Pandora? Until now, the idea that there could be a real-life Pandora in Alpha Centauri seemed like a very long shot. But if S1 is confirmed to be a real planet, there is a high chance that it could have a number of moons. "I would expect that there are probably moons there," Mary Anne Limbach, an exoplanet researcher at the University of Michigan who was not involved in the new study, told NPR. "Moon formation around giant planets generally should be quite common." In our own solar system, for example, the largest gas giants Jupiter and Saturn have a combined 369 natural satellites at the latest count, including sizable moons such as Titan, Europa, Io, Ganymede, Enceladus and Mimas, some of which may even be capable of supporting life themselves. Related: 32 alien planets that really exist But if S1 does have a moon, what are the chances that it can support some form of extraterrestrial life? The answer likely lies in how large it is. Limbach said she is "optimistic" that S1 could support a Mars-size moon, which would make it large enough to have its own atmosphere and large surface oceans, similar to those found on Earth. However, David Kipping, an exoplanet researcher at Columbia University in New York who was not involved in the new study, is more skeptical and told NPR that any moon around S1 would likely only grow to the size of Titan, which is around two-thirds the size of Mars but slightly larger than Mercury. RELATED STORIES —NASA finds signs of hellish, lava-covered 'exomoon' circling an alien world — and it could meet a 'destructive end' —'Unstable' moons may be obliterating alien life across the universe —James Webb telescope's 'shocking' discovery may hint at hidden exomoon around 'failed star' At this size, the moon is unlikely to be able to hold together an atmosphere, making extraterrestrial life — especially on the scale seen in the "Avatar" movies — very unlikely. Therefore, to get a real-life Pandora, "you need this planet to have an unexpectedly big moon," Kipping said, though he added that "it's not impossible." The next challenge, if and when S1 is confirmed to exist, will be to spot any potential exomoons surrounding it. However, this could be tricky as exomoons are notoriously hard to spot, as they are so much smaller and colder than planets. Therefore, we may need to wait for a space telescope several orders of magnitude more powerful than JWST to see anything, which could take decades. Solve the daily Crossword